Hikari Power LTD Bristol Myers Squibb CO Transaction History

Hikari Power LTD

$1.2 Billion
Q3 2024

A detailed history of Hikari Power LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hikari Power LTD holds 29,820 shares of BMY stock, worth $1.76 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

29,820

Previous 29,820 -0.0%

Holding current value

$1.76 Million

Previous $1.24 Million 24.64%

% of portfolio

0.13%

Previous 0.11%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$47.98 - $54.4 $357,930 - $405,824	-7,460 Reduced 20.01%	29,820 $1.62 Million
Q4 2021 Jan 12, 2022	BUY	$53.63 - $62.52 $580,812 - $677,091	10,830 Added 40.95%	37,280 $2.32 Million
Q3 2021 Oct 13, 2021	BUY	$59.17 - $69.31 $438,449 - $513,587	7,410 Added 38.92%	26,450 $1.57 Million
Q2 2021 Jul 07, 2021	BUY	$61.91 - $67.42 $480,421 - $523,179	7,760 Added 68.79%	19,040 $1.27 Million
Q1 2021 Apr 28, 2021	BUY	$59.34 - $66.74 $226,678 - $254,946	3,820 Added 51.21%	11,280 $712,000
Q4 2020 Jan 22, 2021	BUY	$57.74 - $65.43 $430,740 - $488,107	7,460 New	7,460 $463,000
Q2 2019 Aug 08, 2019	SELL	$44.62 - $49.34 $2.77 Million - $3.06 Million	-62,080 Closed	0 $0
Q2 2018 Aug 02, 2018	SELL	$50.53 - $62.98 $784,225 - $977,449	-15,520 Reduced 20.0%	62,080 $3.44 Million
Q4 2017 Jan 12, 2018	SELL	$59.94 - $65.35 $431,568 - $470,519	-7,200 Reduced 8.49%	77,600 $4.76 Million
Q3 2017 Nov 08, 2017	BUY	$55.23 - $63.74 $889,203 - $1.03 Million	16,100 Added 23.44%	84,800 $5.41 Million
Q2 2017 Aug 09, 2017	BUY	N/A	68,700	68,700 $3.83 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hikari Power LTD, based on Form 13F filings with the SEC.

News

Stay updated on Hikari Power LTD with notifications on news.

Account